Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

WHILYAS-2

Financiado

Cerrado

Wound healing ILYA style 2

ILYA PHARMA AB is a Swedish spin-out biotech company from Uppsala that develops next-generation biologics to treat wounds in skin and mucosa. In the previous SME Instrument project, the Company reached the First in Human (FiH) Ph... ver más

31/12/2023

ILYA PHARMA AB

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

ILYA PHARMA AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-12-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

ILYA PHARMA AB

1.36M€ | Lider

ADITIVOS INTELIGENTES

277.43K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-112737RB-I00 DISEÑO DE UN SISTEMA AVANZADO MULTIFUNCIONAL PARA LA LIBERAC... 110K€ Cerrado

NEXTNANO NEXT GENERATION NANOPARTICLE-BASED ANTIBACTERIAL TREATMENT F... 75K€ Cerrado

PID2020-113987RB-I00 APOSITOS TOPICOS FABRICADOS MEDIANTE ELECTROHILADO O POR IMP... 155K€ Cerrado

LASER-HEAL A breakthrough laser based medical device to eradicate bacte... 71K€ Cerrado

InFact Functional materials for fast diagnosis of wound infection 6M€ Cerrado

PHAS Development of a new generation of bioengineered bandages 191K€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2020-11-26
Fecha Fin: 2023-12-31

Líder del proyecto

ILYA PHARMA AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto ILYA PHARMA AB is a Swedish spin-out biotech company from Uppsala that develops next-generation biologics to treat wounds in skin and mucosa. In the previous SME Instrument project, the Company reached the First in Human (FiH) Phase I clinical trial in the development of their technology platform (ILP) that utilizes chemokines as therapeutic agents through local administration from genetically modified lactic acid bacteria. The WHILYAS-2 project addresses several critical problems and unmet medical needs related to the treatment of chronic wounds, both from patients and healthcare perspectives, namely the pandemic of obesity and diabetes (463 million people in 2019), an alarming pace of antibiotic resistance spreading (due to overuse of antibiotics), limited and insufficient treatment options (less than 25% of chronic wounds heal within 12 weeks), and vast and growing socio-economic burden (20 billion EUR per year in the US and Europe alone). The technical, industrial, legal, and commercial feasibility of ILP100 Topical have all been confirmed over the course of our previous activities and developments. In this project, Ilya Pharma intends to conduct exploratory clinical trials (Phase IIa) of their drug candidate, ILP100 Topical, in treatment of non-healing (chronic) wounds in populations with diabetes to achieve clinical Proof of Concept (PoC) in the relevant patient group. WHILYAS-2 will allow the Company to scale up and position it to be further investable for VCs and MedTech/Biopharma Companies or license ILP100 Topical to a partner capable of bringing it to the market through large-scale Phase IIb or pivotal (Phase III) clinical studies. If these efforts are successful, ILP100 Topical is expected to be superior and best in class treatment for chronic wounds, offering ease of use, comparable to traditional wound dressings, >50% reduction of wound infections, significantly reduced 5-year mortality, as well as >50% decrease in treatment cost per wound.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores